Global Tumor Ablation Market, By Type (Thermal Ablation and Chemical Ablation), Types of Treatment (Percutaneous, Laparoscopic, and Surgical), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Liver Cancer, Kidney Cancer, Bone Cancer, and Others), End Users (Hospitals, Oncology Centers, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2030.
Tumor Ablation Market Analysis and Size
The global tumor ablation market is fragmented in nature, as it consists of many global players such as Boston Scientific Corporation (U.S.), Medtronic (U.S.), Olympus (Germany), Stryker (U.S.), and Biotronik (Germany) among others. The presence of these companies produces competitive prices for tumor ablation products across the region. Due to the presence of these players at regional and international levels, suppliers and manufacturers offer products with different specifications and characteristics in all budgets. The rising demand for tumor ablation globally is driving the market growth. Additionally, the rising prevalence of cancer is expected to drive the market growth.
Data Bridge Market Research analyzes that the global tumor ablation market is expected to reach the value of USD 4,225.84 million by 2030, at a CAGR of 13.8% during the forecast period. This market report also covers pricing analysis and technological advancements in depth.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Type (Thermal Ablation and Chemical Ablation), Types of Treatment (Percutaneous, Laparoscopic, and Surgical), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Liver Cancer, Kidney Cancer, Bone Cancer, and Others), End Users (Hospitals, Oncology Centers, and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., France, Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Indonesia, Philippines, Thailand, Malaysia, Singapore, Rest of Asia Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, South Africa, U.A.E., Egypt, Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
Boston Scientific Corporation (U.S.), Medtronic (U.S.), Olympus (Germany), Stryker (U.S.), Biotronik (Germany), Merit Medical Systems. (Utah), HealthTronics, Inc. (U.S.), Insightec. (Israel), AngioDynamics. (New York), Integra LifeSciences (U.S.), Bioventus LLC. (U.S.), Ethicon Inc. (A Subsidiary of Johnson & Johnson) (U.S.), EDAP TMS (Auvergne-Rhône-Alpes), Sonablate Corp. (U.S.), BVM Medical Limited (England), Terumo Europe NV (Belgium), and IceCure Medical (Israel) among others
|
Market Definition
The market includes a wide range of ablation techniques, such as radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, high-intensity focused ultrasound (HIFU), and laser ablation, among others. These techniques utilize different energy sources to deliver controlled heat, cold, or sound waves to destroy tumor cells, leading to their death and subsequent elimination by the body's immune system. The global tumor ablation market encompasses various medical equipment for tumor ablation procedures, including ablation probes, electrodes, needles, catheters, ultrasound systems, MRI systems, and monitoring systems. These devices are designed to precisely deliver the ablation energy to the target tissue while minimizing damage to the surrounding healthy tissues.
Global Tumor Ablation Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
Rising Prevalence of Cancer Globally
The growing prevalence of cancer creates a higher demand for effective treatment options. Tumor ablation techniques offer a minimally invasive alternative to traditional surgery to treat solid tumors. As cancer rates continue to rise, there is an increasing need for treatments that can effectively target and destroy tumors, leading to the growth of the tumor ablation market.
Tumor ablation procedures are particularly valuable for patients with inoperable tumors. These may include tumors in critical or hard-to-reach areas or cases where surgery carries a higher risk due to the patient's overall health condition. Tumor ablation provides a viable treatment option for such patients, allowing tumor destruction without major surgery.
Increasing Inclination of Surgeons and Patients toward Minimally Invasive Procedures
Minimally invasive procedures involve smaller incisions or needle insertions than traditional open surgeries. This results in less tissue damage, reduced blood loss, and lower risk of complications. These procedures typically have shorter hospital stays and faster recovery times. Patients can often resume their normal activities sooner, improving their quality of life.
Minimally invasive techniques often employ advanced imaging technologies, allowing surgeons to visualize and precisely target tumors. This enhances accuracy and helps preserve healthy surrounding tissues. The instruments are designed to provide greater maneuverability and agility, enabling surgeons to perform complex procedures with improved control and precision. The procedures involve smaller incisions, which reduces the risk of post-operative infections compared to open surgeries.
Opportunity
Favourable reimbursement scenario
Favorable reimbursement policies and coverage for tumor ablation procedures ensure that a larger population can access these treatments. When tumor ablation procedures are reimbursed, patients can undergo them without significant financial burden, making them more accessible to a broader patient base. Increased access leads to higher procedure volumes and market growth.
Favorable reimbursement rates and policies incentivize healthcare providers to offer tumor ablation procedures. Adequate reimbursement ensures that providers adequately compensate for the resources, time, and expertise required to perform tumor ablation procedures. This encourages more healthcare facilities and providers to adopt and offer these treatments, driving the market growth.
Restraint / Challenge
Regulatory hurdles for approval
Regulatory approval processes for medical devices and procedures can be lengthy and time-consuming. The process typically involves rigorous evaluation of safety, efficacy, and quality standards, which can delay bringing new tumor ablation technologies to the market. The extended approval timelines can hinder the availability and adoption of innovative tumor ablation solutions, slowing down market growth.
Obtaining regulatory approvals and certifications often requires significant financial resources and expertise. Companies must invest in clinical studies, preclinical testing, and regulatory submissions, which can incur substantial costs. Small and medium-sized enterprises may face financial challenges in meeting these requirements, hindering their ability to market novel tumor ablation technologies. The high cost and resource requirements act as a barrier to entry, limiting competition and innovation in the market.
Recent Developments
- In April 2023, Angio Dynamics. announced an expanded partnership with Cardiva, a Spanish-based medical device company. The partnership builds on an existing collaboration between AngioDynamics and Cardiva, which has successfully distributed AngioDynamics' vascular access portfolio in Spain and Portugal since 2012. The expanded partnership will now include AngioDynamics' oncology portfolio, with the addition of the Italian market in the distribution agreement.
- In September 2020, Boston Scientific Corporation announced that it had signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed field ablation (PFA) system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. This PFA system - comprising a sheath, generator, and catheters - is intended to ablate heart tissue via the creation of a therapeutic electric field instead of using thermal energy sources such as radiofrequency ablation or cryoablation.
Global Tumor Ablation Market Scope
The global tumor ablation market is segmented into five notable segments such as type, types of treatment, cancer type, end users, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Thermal Ablation
- Chemical Ablation
Based on type, the market is segmented into thermal ablation and chemical ablation.
Types Of Treatment
- Percutaneous
- Laparoscopic
- Surgical
Based on the types of treatment, the market is segmented into percutaneous, laparoscopic, and surgical.
Cancer Type
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Liver Cancer
- Kidney Cancer
- Bone Cancer
- Others
Based on cancer type, the market is segmented into breast cancer, lung cancer, prostate cancer, liver cancer, kidney cancer, bone cancer, and others.
End Users
- Hospitals
- Oncology Centers
- Others
Based on end users the market is segmented into hospitals, oncology centers, and others.
Distribution Channel
- Direct Tender
- Retail Sales
Based on distribution channel the market is segmented into direct tender and retail sales.
Global Tumor Ablation Market Regional Analysis/Insights
The global tumor ablation market is analyzed and market size insights and trends are provided by type, types of treatment, cancer type, end users, and distribution channel as referenced above.
The countries covered in this market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Indonesia, Philippines, Thailand, Malaysia, Singapore, Rest of Asia Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, South Africa, U.A.E., Egypt, Israel, Rest of Middle East and Africa.
U.S. is expected to dominate in North America as there is a rising demand for tumor ablation. China is expected to dominate Asia-Pacific as the strategic initiatives by the key market players are expanding significantly. Germany is expected to dominate Europe, due to the rising prevalence of cancer.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Tumor Ablation Market Share Analysis
The global tumor ablation market competitive landscape provides details of the competitor. Details included are company overview, company financials, revenue generated, market potential, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major market players operating in the global tumor ablation market are Boston Scientific Corporation (U.S.), Medtronic (U.S.), Olympus (Germany), Stryker (U.S.), Biotronik (Germany), Merit Medical Systems. (Utah), HealthTronics, Inc. (U.S.), Insightec. (Israel), AngioDynamics. (New York), Integra LifeSciences (U.S.), Bioventus LLC. (U.S.), Ethicon Inc. (A Subsidiary of Johnson & Johnson) (U.S.), EDAP TMS (Auvergne-Rhône-Alpes), Sonablate Corp. (U.S.), BVM Medical Limited (England), Terumo Europe NV (Belgium), and IceCure Medical (Israel) among others.
SKU-